Efficacy and Safety of Lenalidomide Prednisolone Combination Treatment for Japanese Elderly Multiple Myeloma Patients
DOI:
https://doi.org/10.17140/IMOJ-2-106Keywords:
Multiple myeloma, Prednisolone (RP) therapy, Elderly patientsAbstract
Object
Adverse events of steroids such as infections are likely to occur in the elderly patients with multiple myeloma. We examined the efficacy and safety of lenalidomide and prednisolone therapy in which the dosage of steroid was reduced in the elderly patients in Japan.
Method
We retrospectively analyzed 22 elderly relapsed/refractory and newly diagnosed refractory multiple myeloma patients treated at our hospital between January 2011 and February 2015. Treatment efficacy was assessed according to the International Uniform Response Criteria for Multiple Myeloma and adverse events by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Ver. 4.0 Easy R (EZR) was used for statistical analysis.
Result
Complete response (CR), very good partial response and partial response was found in 3, 1 and 18 patients, respectively. The overall three-year survival rate was 58% and time to next treatment was 1 year in 49% of patients. The adverse events were leukopenia (G1-2 23%, G3 9%), anemia (32% G1-2 and 18% G3) and thrombocytopenia (14% G1-2 and 9% G3). Non-hematological adverse events included rash (41% G1-2 and 23% G3), peripheral nerve disorder (23% G1-2, none above G3), and G3-4 renal failure in 10%. Infections of G3 occurred in 5%, and there was no deep-vein thrombosis.
Conclusion
Lenalidomide and low-dose prednisolone can be safely and effectively administered in elderly patients.
References
National Cancer Center Center for Cancer Control and Infor-mation Services: Gan jouhou sa-bisu [Cancer Information Ser-vice], Gan no toukei ’13 [Cancer Statistics ‘13]. Web site. http:// ganjoho.jp/professional/statistics/backnumber/2013_jp.html. Accessed August 30, 2017.
Rajkumar SV, Jacobus S, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexa-methasone as initial therapy for newly diagnosed multiple myelo-ma: An open-label randomised controlled trial. Lancet Oncol. 2010; 11(1): 29-37. doi: 10.1016/S1470-2045(09)70284-0
Dimopoulos MA, Chen C, Stadtmauer EA, et al. Long-term fol-low-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11): 2147-2152. doi: 10.1038/leu.2009.147
Dimopoulos MA, Palumbo A, Delforge M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple my-eloma: Consensus statement. Leukemia. 2011; 25(5): 749-760. doi: 10.1038/leu.2011.3 Submit your article to this journal | https://openventio.org/submit-manuscript/ 6 Hanamoto H, et al
Falco P, Cavallo F, Rocci A, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone con-solidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013; 27(3): 695-701. doi: 10.1038/leu.2012.271
Durie BG, Harousseau JL, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9): 1467-1473. doi: 10.1038/sj.leu.2404284
Dimopoulos MA, Cheung MC, Kolb B, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haemato-logica. 2016; 101(3): 363-370. doi: 10.3324/haematol.2015.133629
Joao C, Freitas J, Gomes F, et al. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. Ann Hematol. 2016; 95(6): 931- 936. doi: 10.1007/s00277-016-2662-6
Kojima A, Tanka Y, Nagai H, et al. Multiple myeloma patients with lenalidomide-associated skin rash have a favorable prognosis. Blood. 2016; 2016: 4532. Original Research | Volume 2 | Number 1|
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Internal Medicine (IMOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.